The announcement at ASCO about that 67% MCyR response from 534 was so impressive! I read it in the ASCO Report which can be found on ARIAD's website. Seems like for sure a 2nd line treatment out the gate. Perhaps a first line treatment eventually. Hopefully, our leaders have the 'know how' on all the vagaries approaching the FDA.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.